Asia Investors Landscape Workshop
Capital from Asian countries has become a significant force behind life science innovations in North America, with Asia-based firms participating in a significant number of Series A & B rounds. There are clear trends emerging in US-Asia cross-border investments in life sciences. Although cross-border deals are considered challenging at times, a good number of Asian investors are willing to take a leading role, including both financially-driven VCs and strategically driven pharma and healthcare firms based throughout the Asia region. This workshop will explore the trends driving this evolving capital landscape.
Lucy Parkinson, VP of Investor Research, Life Science Nation
Lucy Parkinson is LSN’s VP of Investor Research, and leads LSN’s investor outreach and analysis team. She additionally contributes to LSN’s web marketing as the voice of LSN’s videos and a contributing writer on both The Life Science Executive’s Fundraising Manifesto and the Next Phase newsletter. Prior to joining LSN, Lucy spent several years working at CPA firms, gaining experience working with small corporations, partnerships and nonprofit organizations. Lucy graduated from the University of Leeds with a degree in the History and Philosophy of Science. She is also a FINRA-registered securities principal and an Enrolled Agent.
James Huang, Research Analyst, Life Science Nation
James Huang is a Research Analyst for LSN in Boston, Massachusetts. Previously, James served as a Research Assistant in the Hematology Division at Washington University in St. Louis, growing modified TFPI and developing assays to detect the efficiency of these mutations. Previously, he served as an analyst at Informulary, a start-up dedicated to analyzing FDA clinical trial data and systematic review data to extract relevant data for use in more easily understood drug labels and for use in advising self-insured employers determine medications to be covered in their formularies. Currently, as a Research Analyst at Life Science Nation (LSN), he collaborates with investors in various life science sectors such as therapeutics, medical devices, diagnostics, and healthcare IT. James also works closely with many Chinese investors and has written articles on the Chinese market based on conversations with these investors and research he has done on the topic. James received his B.A. in Neuroscience from Dartmouth College.